| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 959.34 KB | Adobe PDF |
Authors
Abstract(s)
A artrite psoriática (APso) afeta frequentemente mulheres em idade reprodutiva. O
secucinumab (SEC) é um anticorpo monoclonal contra a interleucina 17A (IL17A) e é
eficaz no controlo da progressão das manifestações articulares e cutâneas da APso. No
entanto, este não foi extensivamente estudado na gravidez, apesar de estarem relatados
292 casos de exposição ao fármaco, com resultados de segurança tranquilizadores.
Atualmente, a sua utilização está categorizada como não aconselhável em mulheres
durante o período gestacional, devido a não existirem dados suficientes sobre os seus
efeitos tóxicos. A presente dissertação será um estudo de caso de uma gestante do
Hospital Amato Lusitano, em Castelo Branco, sob terapêutica com SEC, para
tratamento de APso. Esta utente, será a primeira gestante a ser documentada, em
Portugal, sob terapêutica biológica.
Os tópicos desta dissertação serão expostos no índice a seguir.
Psoriatic arthritis (PsA) often affects women of reproductive age. Secukinumab (SEC), a monoclonal antibody against interleukin-17A (IL17A) is effective in contrasting the progression of articular and cutaneous manifestations of PsA but has not been extensively studied in pregnancy, despite 292 cases of exposure reported with reassuring safety outcomes. The objective to present this case is to evaluate the maternal and fetal outcomes in a woman with PsA exposed to SEC during pregnancy, the first case occurred in Portugal. Currently, the use of this biologic is categorized as not advised to use during pregnancy derived from the fact that there is not sufficient data about it´s possible toxic effects. This dissertation is a case report about a woman from the Amato Lusitano Hospital, in Castelo Branco, under monthly treatment for PsA with SEC during her first pregnancy. This patient will be the first to be documented in Portugal. The topics of this dissertation will be exposed in the index ahead.
Psoriatic arthritis (PsA) often affects women of reproductive age. Secukinumab (SEC), a monoclonal antibody against interleukin-17A (IL17A) is effective in contrasting the progression of articular and cutaneous manifestations of PsA but has not been extensively studied in pregnancy, despite 292 cases of exposure reported with reassuring safety outcomes. The objective to present this case is to evaluate the maternal and fetal outcomes in a woman with PsA exposed to SEC during pregnancy, the first case occurred in Portugal. Currently, the use of this biologic is categorized as not advised to use during pregnancy derived from the fact that there is not sufficient data about it´s possible toxic effects. This dissertation is a case report about a woman from the Amato Lusitano Hospital, in Castelo Branco, under monthly treatment for PsA with SEC during her first pregnancy. This patient will be the first to be documented in Portugal. The topics of this dissertation will be exposed in the index ahead.
Description
Keywords
Artrite Psoriática Gravidez Psoríase Secucinumab Terapêutica Biológica